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Abstract: In hypertension and diabetes, early structural changes of the arterial wall precede or 
support atherosclerosis. There is evidence that some antihypertensive drugs exert an antiathero-
sclerotic effect. Over 36 months, we investigated the effect of candesartan cilexetil (CC) on the 
common carotid intima-media thickness (IMT) vs amlodipine besylate (AML) in patients with 
type 2 diabetes and mild to moderate essential hypertension. After a 4-week wash-out period, 
209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum 
of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the 
addition of hydrochlorothiazide 12.5 mg if necessary. No signiﬁ  cant differences were observed 
between the two groups for change in IMT at M12 (−0.001 vs −0.027 mm/year for CC and 
AML respectively, p = 0.425), at M24 (−0.033 vs −0.019 mm per year respectively, p = 0.442), 
and at the last visit (−0.016 vs −0.039 mm per year respectively, p = 0.549). Within the group, 
comparisons did not show a signiﬁ  cant difference in changes in IMT from baseline to the three 
visits. At the last visit, IMT regression was observed in 52.2% of patients receiving CC and in 
51.3% of those receiving AML (p = 0.908). The augmentation in carotid lumen diameter from 
baseline was statistically greater in the AML group at the last visit (p = 0.034). BP variations 
during the study were similar in the two groups. The results of this study show that CC and 
AML treatments may alter identically the natural progression of carotid IMT in hypertensive 
type 2 diabetic patients.
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Introduction
Hypertension is present in more than 50% of patients with diabetes. Hypertension 
and diabetes are two cardiovascular risk factors leading to atherosclerosis, which 
is the source of most cardiovascular complications.1 In hypertension and diabetes, 
early structural changes of the arterial wall, with or without hypertrophy, precede or 
support atherosclerosis. Early lesions of atherosclerosis can be detected by noninvasive 
examination, such as ultrasonography of the carotid artery, and are powerful predictors 
of future cardiovascular events.2,3 This method has been used in several therapeutic 
trials.4 Carotid ultrasonography is a painless, reliable and reproducible examination 
which makes it possible to measure the intima-media thickness at different points on 
the carotid artery (CIMT). Detection of the early phases of atherosclerosis is essential 
from a diagnostic and therapeutic point of view, and improves the knowledge of 
pathophysiological mechanisms. Improving the control of hypertension and diabetes can 
reduce the progressive plaque formation associated with arterial wall thickening.
There is evidence that antihypertensive drugs, or at least some classes of antihy-
pertensive drugs, in particular calcium antagonists and angiotensin converting enzyme 
inhibitors, exert an antiatherosclerotic effect that is partly independent of the blood 
pressure (BP)-lowering effect of these drugs.5,6Vascular Health and Risk Management 2009:5 176
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Candesartan cilexetil (CC) is a selective AT1 subtype 
angiotensin II receptor antagonist (ARB). Clinical studies 
in over 9000 patients proved candesartan to be an effective 
and well-tolerated treatment for hypertension. Meta-analyses 
of 6 placebo-controlled European studies showed that the 
average reduction in diastolic BP (DBP) is approximately 
5.6 mmHg (95% conﬁ  dence interval [CI]: 4.3–7 mmHg) at 
a dose of CC 8 mg per day.7 The average reduction in DBP 
observed when the dose is doubled to 16 mg is approximately 
7.1 mmHg (95% CI: 5.5–8.6 mmHg). The average fall in 
DBP when the 8 mg dose is taken in association with hydro-
chlorothiazide (HCTZ) is approximately 7.9 mmHg.7
Amlodipine besylate (AML) is a second-generation 
dihydropyridine calcium antagonist, effective in the treatment 
of hypertension. The beneﬁ  cial action of AML on the CIMT 
was highlighted in several studies.8–10 The mechanism of 
AML in slowing down CIMT progression seems to be due 
not only to reduction of the pulse pressure (PP) but also to a 
direct antiatherogenic effect of AML.
The objective of this study was to evaluate the effect 
of CC compared with AML on the CIMT using ultrasound 
methods in patients with type 2 (non-insulin dependent) 
diabetes and mild to moderate essential hypertension.
Materials and methods
Study design
The design features have been previously reported11 and are 
summarized as follows. MITEC (Media Intima Thickness 
Evaluation with Candesartan cilexetil) was a multicenter, 
randomized, double-blind, active controlled, and parallel-
group study conducted in France, in hypertensive type 
2 diabetic patients. The objective was to evaluate the effect of 
CC in the progression of CIMT over 36 months in comparison 
with AML.
The study was conducted in hospital departments or 
private physicians’ offices. Investigators participating 
in the study were cardiologists or general practitioners. 
The trial was carried out in accordance with the Helsinki 
Declaration, and the French law for biomedical research, 
and was approved by the local Research Ethics Committee 
of Grenoble (France). All subjects gave written informed 
consent. The study coordinating committee could stop the 
study prematurely if necessary.
Study population
Ambulatory men or women (40–74 years old) were 
randomized if there was evidence of mild to moderate 
(140/90   BP   180/110 mmHg), essential, non-complicated 
hypertension with type 2 diabetes treated by diet and/or oral 
hypoglycemic agents, stable for at least 3 months. Hyperten-
sion, deﬁ  ned according to ESH–ESC 2003 guidelines12 had 
either been recently diagnosed and not previously treated, 
or previously unsuccessfully treated in terms of efﬁ  cacy or 
tolerability. In addition, patients had to disply: a common 
CIMT, measured by ultrasonography, of  0.6 and  1.2 mm 
(measured in 5 places by ultrasonography callipers); total 
cholesterol  2.5 g/L, triglycerides  4 g/L and low-density 
lipoprotein (LDL) cholesterol  1.6 g/L (under lipid lowering 
drugs or not); HbA1c   10%; compliance to the single-blind 
placebo treatment during run-in of between 80% and 120% 
(evaluated by counting returned capsules). Dyslipidemia was 
demonstrated by elevation of total cholesterol, LDL-cholesterol 
or triglyceride concentrations, or a decrease in high-density 
lipoprotein (HDL) cholesterol concentration in the plasma.
Patients were not included if they had: type 1 (insulin-
dependent) diabetes, type 2 diabetes requiring insulin, 
secondary diabetes, secondary or malignant hypertension, 
severe hypertension at rest (systolic BP [SBP]   180 mmHg 
and/or DPB   110 mmHg), congestive heart failure, myocardial 
infarction or stroke during the previous 6 months, cardiac 
arrhythmia, previous carotid surgery or stenting, signiﬁ  cant 
carotid stenosis, non-validated carotid ultrasonography, severe 
renal insufﬁ  ciency, abnormal hepatic function tests.
Interventions
After a 4-week placebo wash-out period, patients were 
randomized to receive either CC 8 mg or AML 5 mg once 
daily, encapsulated for blinding purposes. Randomization 
was computer generated and balanced by the center. If BP 
was not normalized at any follow-up visit (from M1 to M33), 
ie, SBP   130 mmHg or DBP   85 mmHg, the treatment 
could be doubled. If BP was still not normalized, HCTZ 
12.5 mg (half a 25 mg oral tablet) had to be administered 
daily. After 3 months of uncontrolled BP, patients were 
excluded from the study due to efﬁ  cacy failure. No return to 
a former posology after adjustment was allowed.
Carotid ultrasonography
Carotid ultrasonography was made at baseline and yearly 
thereafter (M12, M24, and M36). For each center, baseline 
and follow-up studies were performed in a standard 
fashion by a single specialist physician who was specially 
trained to do the prescribed study examination. B-mode 
ultrasonography was performed on a single ultrasound 
machine with a 7.5 MHz sector scanner probe (axial and 
lateral resolution  0.25 mm) as previously described.13 Vascular Health and Risk Management 2009:5 177
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Both common carotid arteries were studied consecutively 
in the long axis with probe incidence allowing good quality 
images. A zoom was used to deﬁ  ne a zone of interest of 
20 mm in length (stretching from 10 to 30 mm above the 
carotid bifurcation). A good image was deﬁ  ned by the pres-
ence of two hyper-echogenic lines, separated by a hypo-
echogenic zone, from the posterior artery wall. The IMT was 
deﬁ  ned as the distance separating the most internal parts of 
these lines (B mode image of intima plus media thickness) 
and the luminal diameter by the distance between the blood-
intima interfaces on the anterior and posterior walls.14 All 
images were stored electronically and analyzed by speciﬁ  c 
software (TIMC laboratory, CHU Grenoble, France). IMT 
and diameter were measured semi-automatically on areas 
free of atheroma. The mean number of measurements of 
common carotid IMT at each site was 122 ± 15. The value 
of CIMT for any subject was the mean value for the two 
common carotid arteries. An independent observer who was 
blinded to treatment group and trained in the interpretation 
of CIMT images performed off-line analysis of B-mode 
ultrasound images. Regression in CIMT between two visits 
was deﬁ  ned by a reduction in IMT whereas progression was 
noted in case of an increase in IMT.
Blood pressure assessment
At each visit, BP was measured just before carotid 1 using 
a mercury sphygmomanometer according to ESH–ESC 
guidelines.12 BP was measured in the sitting position after 
5 minutes of rest, 3 times at 1-minute intervals, the average 
being used to deﬁ  ne ofﬁ  ce values. BP was measured once 
more after 1 minute in the standing position.
Safety assessments
All adverse events (AEs) reported by the patients or observed 
by the investigator were recorded in the case report form at 
each visit whatever the causal relation to treatment. AEs have 
been reported to the appropriate drug licensing authority and to 
the drug manufacturer. An ECG and biological measurements 
were performed prior to each visit. Biological measurements 
were performed after an overnight fast of at least 12 hours and 
included: plasma creatinine, creatinine clearance (Cockroft 
formula) sodium, potassium, glucose, hemoglobin A1c 
(HbA1c), total cholesterol, HDL cholesterol, triglycerides and 
LDL cholesterol (calculated by the Friedwald formula).
Statistical analysis
Sample size calculation assumed a 3-year difference in CIMT 
changes between treatments groups of 0.05 mm with a 
standard deviation of 0.10 mm. With two sided 5% signiﬁ  cance, 
95% power, and 30% drop-out rate, a total sample size of 
220 patients was aimed to be recruited into the study.
The efﬁ  cacy criteria were evaluated in the per-protocol 
population. Due to the small number of patients reaching 
M36, the changes in CIMT were analyzed at M12, M24, and 
at the last available visit.
Changes in CIMT for each treatment were compared 
using Student’s t-test; a Wilcoxon test was performed if 
the data were not normally distributed. Changes in the 
other quantitative variables were analyzed similarly. The 
qualitative variables were analyzed using a chi-squared test 
or the degree of signiﬁ  cance calculated using Fisher’s exact 
test. Pearson’s coefﬁ  cient was used to analyze the correlation 
between the CIMT values and other variables as follows: 
demographic and clinical characteristics, BP measurements, 
and biological laboratory values classically considered as 
cardiovascular risk factors, at M0, M12, M24 and at the last 
visit; p   0.05 was deemed to indicate signiﬁ  cance.
Results
Patients
A total of 254 patients were selected from 131 sites and 
entered in a 4-week, single blind, placebo run-in/wash-out 
period (Figure 1). Among these, 209 were randomized and 
allocated to CC (n = 100) or AML (n = 109). During the 
follow-up, 98 patients discontinued the study prematurely 
(43% in CC group vs 50.5% in AML group). AML patients 
exhibited more AEs related to treatment than CC patients, 
which led to early study discontinuation (Figure 1). 
Furthermore, AML patients (21.2%) discontinued more 
frequently for uncontrolled hypertension than CC patients 
(12%). The study design did not allow an increase in doses 
of treatment if patients were not controlled with 16 mg 
of CC or 10 mg of AML, with or without 12.5 mg HCTZ 
association. This led to a signiﬁ  cant number of withdrawals 
for lack of efﬁ  cacy (16.7%), and a signiﬁ  cant number of 
patients (46.8%) did not complete the planned 36-month 
treatment period. It was the decision of the study coordinating 
committee and sponsor to stop the study prematurely.
Characteristics of study population 
at baseline
The baseline characteristics are given in Table 1. Patients, 
principally male (63.6%), were 59.7 ± 8.5 years old. There 
was good comparability of baseline characteristics between 
groups, except for the presence of dyslipidemia (p = 0.027) 
which was more frequent in the AML group.Vascular Health and Risk Management 2009:5 178
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Figure 1 Flow of patients through the trial.
The median time since diagnosis for hypertension 
and diabetes was 5.9 years (0–41) and 4.7 years (0–36), 
respectively. Hypertension was treated for 75.6% of patients, 
and the majority (57.9%) received more than 3 treatments. 
Diabetes was treated by an appropriate diet (21.2%), or a 
diet in association with antidiabetic treatment (63.4%), or 
only with antidiabetic treatment (14.1%). Oral antidiabetic 
treatments were mainly sulfonylureas and biguanides.
The CIMT at baseline was positively correlated to HbA1c 
(p = 0.032), creatinine (p = 0.014) and age (p   0.001), and 
negatively to creatinine clearance (p = 0.005).
Changes in the carotid wall
CIMT
During the ﬁ  rst year, the CIMTmedian decrease was −0.001 mm 
per year and −0.027 mm per year for CC and AML regimen 
treatment respectively (p = 0.425). During the second year 
of treatment, the CIMTmedian decrease was −0.033 mm/year 
and −0.019 mm per year for CC and AML regimen treatment 
respectively (p = 0.442).
A reduction in the CIMTmedian was observed at the last 
visit in the CC group and the AML group, with no statistical 
difference between treatments (p = 0.549).
Within the group, comparisons did not show a statistically 
signiﬁ  cant difference in the changes in CIMT from baseline 
to M12, M24, or to the last visit. There was no difference 
observed between treatment groups in any of the M12, M24, 
and last visit CIMT measurements (Table 2). At the last visit, 
CIMT regression was observed in 56.5% of patients receiving 
CC and 59.0% of those receiving AML (p = 0.820), compared 
with the baseline visit.
Carotid lumen diameter
Carotid lumen diameter changed slightly with CC and AML 
regimen treatment. The increase in carotid lumen diameter from 
baseline was statistically greater in the AML group at the last 
visit (p = 0.034). However, there were no signiﬁ  cant changes 
from baseline within each treatment group (Table 2).
Cross-sectional area
A trend towards a decrease in cross-sectional area was 
observed. However, the SD values indicate important 
dispersion. The changes in cross-sectional area, at M12, at 
M24, and at the last visit from baseline were not signiﬁ  cant 
within each treatment group (Table 2, Figure 3) and did not 
differ signiﬁ  cantly between groups (p = 0.089).
Treatment-related changes in blood pressure, heart 
rate, and biological parameters BP normalization were 
seen from the third month of treatment in 51/88 patients 
(58%) from the CC group and 49/93 patients (51.6%) from Vascular Health and Risk Management 2009:5 179
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Table 1 Characteristics of the study population at baseline (intent to treat population)
Candesartan N = 100 Amlodipine N = 109 p
Male sex, n (%) 60 (60.0) 73 (67.0) 0.295
Age, years 59.7 ± 8.6 59.7 ± 8.4 0.755
BMIa, kg/m² 31.0 ± 5.6 30.3 ± 4.8 0.540
Glucose, g/L 1.6 ± 0.5 1.5 ± 0.4 0.774
HbA1c, % 7.1 ± 1.5 7.0 ± 1.1 0.778
Creatinine, mg/L 8.8 ± 1.6 9.1 ± 2.3 0.564
Creatinine clearancea, mL/min 108 ± 37 107 ± 34 0.902
Serum lipids, g/L
 Total  cholesterol 2.0 ± 0.3 2.1 ± 0.4 0.763
 LDL  cholesterol 1.2 ± 0.3 1.2 ± 0.3 0.794
 HDL  cholesterol 0.5 ± 0.1 0.5 ± 0.1 0.151
 Triglycerides 1.6 ± 1.3 1.7 ± 1.0 0.329
Lipid disorders, % 52 (52.0) 73 (67.0) 0.027
BP, mmHg
 Systolic  BP 156 ± 12 156 ± 11 0.820
 Diastolic  BP 91 ± 8 92 ± 8 0.283
 Pulse  pressure 65 ± 12 64 ± 11 0.247
Heart rate, bpm 74 ± 9 73 ± 9 0.358
Note: Results are given as mean ± SD.
aCalculated by the Cockcroft formula.
Abbreviations: BMI, body mass index; BP, blood pressure.
AML, and progressively increased in both groups: 54.8% 
(40/73 patients) and 57.7% (41/71 patients) at M12, and 
61.5% (24/39 patients) and 65.8% (25/38 patients) at M24 
(Figure 2).
At the ﬁ  nal visit, ofﬁ  ce BP decreased markedly (p   0.001) 
and equally in both treatment groups: −25/−14/−11 mmHg 
and −25/−16/−10 mmHg for SBP, DBP, and PP values in 
CC (n = 36) and AML (n = 33) groups, respectively. No 
signiﬁ  cant changes were observed in heart rate.
Serum lipids, glucose, and HbA1c did not show 
differences between baseline and the last visit. Creatinine 
increased by 0.6 mg/L and 1.2 mg/L in the CC and AML 
groups, respectively. Creatinine clearance fell signiﬁ  cantly 
by −8 mL/min (p   0.001) and −14 mL/min (p = 0.002) in 
the CC and AML groups, respectively. No correlations were 
found between changes in CIMT and BP measurements.
Treatment adaptation and concomitant 
treatments
At M12, 17 (23%), 18 (25%), and 38 (52%) of the patients 
treated with CC (n = 73 evaluated) received a low-dose mono-
therapy, a double dose, or add-on HCTZ, respectively. Of 
the patients treated with AML (n = 71 evaluated), 22 (31%), 
24 (34%), and 25 (35%) received low-dose monotherapy, a 
double dose, or add-on HCTZ, respectively.
At M24, of the patients treated with CC (n = 39 
evaluated), 7 (18%), 12 (31%), and 20 (51%) received a 
low-dose monotherapy, a double dose or add-on HCTZ, 
respectively, while of the patients treated by AML (n = 38 
evaluated), 14 (37%), 12 (31.5%), and 12 (31.5%) received 
low-dose monotherapy, a double dose, or add-on HCTZ, 
respectively.
Anti-diabetic agents and lipid-lowering treatments 
were given during the treatment period. At M12, 106/146 
patients (72%) received an antidiabetic agent and 72/147 
patients (49%) received a lipid-lowering treatment. At 
M24, of the 78 patients evaluated, 59 (75.6%) received 
an antidiabetic and 38 (48.7%) patients received a lipid-
lowering agent.
Safety
Signiﬁ  cantly more AEs related to the study drug occurred 
in the AML group than in the CC group (32.1% vs 13.0% 
respectively, p = 0.001). The number of serious AEs was not 
statistically different between the two groups. During the 
study, 21 patients (10%) withdrew due to adverse events, Vascular Health and Risk Management 2009:5 180
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5 patients from the CC group and 16 patients from the AML 
group. No patient died during the study.
Discussion
This is the ﬁ  rst study to date, to our knowledge, to assess the 
efﬁ  cacy of CC on CIMT progression in diabetic patients. 
The principal results of the MITEC study showed that anti-
hypertensive treatment with CC decreased CIMT in diabetic 
patients to the same extent as treatment with AML. Looking at 
the change in CIMT from baseline to the last visit, the median 
values fell with both CC and AML regimen treatments. This 
fall was not statistically signiﬁ  cant between or within groups, 
but represents a tendency. Our results failed to support the 
hypothesis that CC was superior to AML but showed a similar 
effect of both treatments in diabetic patients.
It is important to note that MITEC was prematurely 
stopped due to the number of patients discontinuing the 
study mainly due to lack of antihypertensive efficacy 
(CC 12% and AML 21%). The number of patients evaluated 
in the per-protocol population was smaller than required in the 
study design to achieve a statistically signiﬁ  cant conclusion. 
Premature withdrawals can be explained by several factors. 
A total of 57.9% of randomized patients required at least 
3 anti-hypertensive drugs. Among these patients, replacement 
of the treatment with a placebo during the ﬁ  rst month and the 
impossibility of intensifying the antihypertensive treatment, 
after up-titration and addition of HCTZ 12.5 mg, are likely 
to have inﬂ  uenced the decision to stop trial participation. If 
not controlled, the progression of BP levels in these diabetic 
patients would have created worsening conditions for the 
vessels and the atherosclerotic lesions with increasing 
arterial stiffness. A previous study with similar doses of 
AML,10 which demonstrated a signiﬁ  cant decrease in CIMT 
(−0.048 mm) compared with lisinopril (−0.027 mm), allowed 
doxazosin and bendroﬂ  uazide as second- and third-line 
therapies, in case of unacceptable control.
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Altogether, the rigid study therapy regimen and the reduced 
ﬁ  nal analysis population contributed to a lack of statistically 
signiﬁ  cant ﬁ  ndings for CIMT. However, a downward trend 
in CIMT values deserves further investigation into the role of 
CC in reducing CIMT in hypertensive patients with diabetes. 
Supporting our results, a recent study conducted in hyperten-
sive patients demonstrated the role of CC in reducing CIMT 
after 52 weeks of treatment.15
It was previously described that healthy subjects show 
a progression in CIMT values of 0.007 to 0.008 mm per 
year.16,17 In the study by Hanefeld et al18 patients with 
glucose intolerance and treated with placebo had an annual 
progression rate of 0.013 mm per year, which is almost 
twice that of healthy subjects. Patients with type 2 diabetes 
exhibited a higher annual increase in CIMT (+0.02 mm per 
year).19 The effects of some antidiabetic agents, arcabose vs 
placebo,18 repaglidine vs glyburide,20 or the insulin sensitizer 
rosiglitazone vs placebo,21 on CIMT progression have been 
principally tested in diabetic patients while studying oral 
antidiabetics. Other studies tested the effects on CIMT 
progression in hypertensive or coronary artery disease patients 
by using antihypertensive treatments: AML vs placebo,8 
AML vs lisinopril,10 ramipril vs placebo,19 nifedipine vs 
co-amilozide,22 or lacidipine vs atenolol.23 Pitt et al8 described 
the competence of AML in patients with coronary artery 
disease for the ﬁ  rst time and showed a signiﬁ  cant reduction 
of CIMT vs placebo. The SECURE study19 examined the 
effect of 10 mg ramipril, an angiotensin converting enzyme 
inhibitor, on CIMT during a 4-year follow-up where annual 
progression was reduced to 0.018 mm with ramipril, vs 
0.022 mm (p = 0.033) in the placebo group.
Our patients combined both hypertension and diabetes. 
The search for a correlation between CIMT values and 
various parameters showed only a correlation with age, 
a main correlation factor observed in other studies.24 The 
metabolic parameters were well controlled and stable 
throughout the study. In the patients who remained in the 
study with CIMT measurements available, both treatments, 
CC and AML, were effective in managing hypertension, as 
assessed by the fall in measured BP. Although BP was not 
associated with CIMT at baseline, the fall in BP seems to 
play an important role in decreasing CIMT values. However, 
our data do not exclude a signiﬁ  cant role for the decrease in 
PP, particularly local carotid PP,25 or antiatherogenic effects 
with both drugs.
Preliminary evidence suggests that a decrease in BP is 
associated with diminished wall thickness.10 It is not known if 
all classes of antihypertensive agents have similar protective 
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effects. Comparing our results with those in the literature, 
the regression for CIMT values in 56.5% of diabetic patients 
treated with CC is an exciting and promising result. Further 
research must be conducted with a large number of patients 
to conﬁ  rm these results.
It has been shown that CIMT progression rates measured 
at the internal carotid artery rather than the common carotid 
artery detect greater absolute changes in CIMT and are better 
correlated with cardiovascular risk factors. The results of a 
3-year study of a community population showed that mean 
CIMT progression was signiﬁ  cantly greater at the inter-
nal carotid (0.032 ± 0.109 mm per year) than the carotid 
bifurcation (0.023 ± 0.108 mm per year) and common 
carotid artery (0.001 ± 0.040 mm per year) (p   0.001).26 
Furthermore, only the internal CIMT correlated signiﬁ  cantly 
with baseline risk factors (age, male gender, hypertension, dia-
betes, and smoking). Observing these site-speciﬁ  c differences 
may be important in future studies testing the effects of anti-
hypertensive drugs on vascular remodelling and CIMT.
The changes in cross-sectional area showed a similar 
trend in both treatment groups. The lumen diameter was 
enlarged under AML but not under CC, principally due to 
the higher vasodilatation effect of AML than with CC.
The changes in CIMT observed in the present study and 
the disparate vascular remodeling seen in the two treatments 
groups may not be attributable only to the direct action of 
the drugs on the arterial wall, but also to differences in local 
hemodynamics, and shear and tensile stresses within the 
carotid artery. AML, a member of the long-acting highly 
lipophylic dihydropyridines, has a marked inhibitory inﬂ  uence 
on the oxygen-free radicals involved in lipid peroxidation and 
has been shown to prevent experimental atherosclerosis.
ARBs have been shown to cause outward remodeling in 
resistance arteries,27 which may be related to vasodilation.28 
A previous study29 reported that ARB losartan reduced CIMT 
to a similar extent to atenolol. However, a small substudy of 
the LIFE trial showed a signiﬁ  cant decrease in CIMT with 
losartan therapy, but not with atenolol therapy, after 3 years of 
treatment.30 Another study31 reported that an 8-week treatment 
with irbesartan decreased radial artery wall thickness in com-
parison with placebo but did not affect CIMT or lumen diameter. 
Factors inﬂ  uencing the carotid lumen diameter are not well 
understood.15,27,28,30,31 Ariff et al15 proposed that arterial remod-
elling acts to preserve levels of endothelial shear stress but, in 
his study, shear stress did not change with treatment despite 
the different effects on lumen diameter and carotid blood ﬂ  ow 
(CBF). Measurement of CBF suggested that CC was associated 
with a decrease in cerebrovascular resistance which is consistent 
with previous results which showed that ARBs act as cerebral 
vasodilators.32 In our study CBF was not measured.
The differences between these studies may relate to small 
sample sizes, the non-equivalence of BP reduction, or vari-
able duration of therapy. The sample size of our study did 
not allow us to speculate. Further investigation will help us 
to elucidate these preliminary observations.
The total incidence of AEs was comparable between 
the two groups. However, a signiﬁ  cantly greater number of 
AEs related to treatment was observed in the AML group 
compared with the CC group.
In conclusion, this study shows for the ﬁ  rst time that 
CC and AML treatments can decrease CIMT in more than 
half of type 2 diabetic patients with hypertension. Even if 
this study was not placebo designed for ethical reasons, the 
present data strongly suggest that both drugs may alter the 
natural progression of CIMT in such patients, mainly as a 
result of BP lowering, the beneﬁ  cial effect of CC in vascular 
remodeling deserves to be conﬁ  rmed in a bigger sample of 
diabetic patients with or without hypertension.
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Figure 3 Cross-sectional area (CSA) values at baseline (M0), M12, M24, and at last visit in hypertensive diabetic patients treated by candesartan cilexetil (CC) or amlodipine 
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